Visit DOTmed at RSNA, North Hall B, Booth #6608 -- Ask about Clean Sweep Equipment Auctions

Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Send us your Comments

Never Miss a Story

Sign up for email alerts


More Industry Headlines

RSNA: Raising the bar on breast tomosynthesis The benefits of C-View software for improving the new standard in breast imaging

RSNA: FUJIFILM announces two major new DR innovations World's first long-length DR detector and FDR Visionary Suite

New scattered X-ray method delivers a whole new view of your tooth Measuring structures as small as a billionth of a meter

Breast MR after mammography may catch additional aggressive cancers How clinically significant are multicentric cancers?

Will the future hold compact, tunable X-ray devices made of graphene? May reduce radiation dose and cost associated with current X-ray devices

Dell announces entry into health care monitor market New device is designed to meet IEC 60601-1 standard

Bilingual patients have better cognitive function after stroke But it may not apply to all bilingual people

Canadian hospital clerk who sold maternity records fined $27,000 — hospital facing $308.4 million suit From 1995 to 2014 she sold at least 14,450 records

Google Glass used to treat blocked coronary artery for first time A more economical option

UnitedHealth scaling back efforts in ACA exchanges May quit them entirely in 2017

Imaging biomarkers enable early diagnosis
and assessment of treatment

Siemens Opens Research Facility for Molecular Imaging Biomarkers

by Barbara Kram , Editor
LOS ANGELES and HOFFMAN ESTATES, Ill. - Siemens Medical Solutions has opened a new state-of-the-art research facility dedicated exclusively to the development of molecular imaging biomarkers, which will become in vivo diagnostic tools for identifying debilitating diseases such as cancer, and neurological diseases at their earliest stages.

The opening of the Siemens Medical Solutions Molecular Imaging (MI) Biomarker Research facility is the latest step for the company in becoming the world's first full-service diagnostics company, integrating in vivo and in vitro imaging diagnostics capabilities. Siemens recently launched Siemens Medical Solutions Diagnostics as the in vitro complement to the portfolio on the heels of acquisitions of Bayer Diagnostics and Los Angeles-based Diagnostic Products Corporation.

Story Continues Below Advertisement

Workflow intelligence optimizes priority of reads

It only takes one delayed reading with a bad outcome to lead to a disaster. Click to read about a workflow intelligence system that makes sure the most urgent cases get read first and on time.

"Molecular medicine is heralding a new era in diagnostic capabilities that could change the lives of millions of Americans - and Siemens is helping lead the field out of the research lab and into practical use," said Michael Reitermann, president, Molecular Imaging division, Siemens Medical Solutions. "Advancing this field brings with it the promise of personalized therapeutics, which would not only improve the efficiency of health care, but most importantly, would also improve the quality of health care for patients."

Siemens Medical Solutions MI Biomarker Research facility will be dedicated solely to the discovery and development of new imaging biomarkers to spur the growth of in vivo molecular diagnostics. Imaging biomarkers are molecules that are specifically designed to seek out disease indicators that may appear in individual cells or tissue in the organism and that may provide early warning signs of disease. Once these imaging biomarkers bind to the diseased cells or tissues, they cause them to "light up" when scanned using PET (Positron Emission Tomography, CT(Computed Tomography) or SPECT(Single-Photon Emission Computed Tomography).

Imaging biomarkers not only enable early diagnosis, but also allow the measurement of how well certain therapies, such as prescription drugs, chemotherapy and radiation therapy, may be working by measuring the impact of treatments on the disease indicators. This may aid the development of new therapies, and enable clinicians to non-invasively assess therapeutic success and quickly adjust therapeutic approaches to arrive at optimum outcomes.

The new Siemens' facility will be led by Hartmuth Kolb, Ph.D, vice president, Siemens Medical Solutions MI Biomarker Research. The facility will house scientists, dedicated to the discovery of new imaging agents and their clinical development, with the goal of bringing several new agents to the market over the next 5 - 10 years. Research and development efforts conducted at the facility will focus largely on oncology and neurology, and also include other areas such as inflammation and microfluidics/nanotechnology research.

Continue reading Siemens Opens Research Facility for Molecular Imaging Biomarkers...
  Pages: 1 - 2 >>


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2015 DOTmed.com, Inc.